secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vanda Pharmaceuticals Inc. (VNDA)
CIK:        0001347178
Form:       8-K
Filed at:   2024-06-20T23:59:59+00:00
Accession:  0001193125-24-164545
Event type: m_and_a
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vanda Board rejects two unsolicited takeover proposals, citing undervaluation
-----------------------------------------------------------------------------

- Cycle Group bid $8.00/share cash; Future Pak offered $8.50-$9.00/share plus CVRs.
- Board determined both proposals substantially undervalue Vanda and not in best interests.
- Board cites robust revenue, strong cash position, and clinical pipeline as intrinsic value.
- No shareholder action required at this time.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1347178/000119312524164545/0001193125-24-164545-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1347178/000119312524164545/d844822d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-164545

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer